Nippon Life Global Investors Americas’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10.6M | Sell |
42,080
-10,270
| -20% | -$2.21M | 0.42% | 52 |
|
|
2026
Q1 | $11.4M | Buy |
52,350
+6,100
| +13% | +$1.35M | 0.51% | 46 |
|
|
2025
Q4 | $10.6M | Sell |
46,250
-1,720
| -4% | -$392K | 0.44% | 47 |
|
|
2025
Q3 | $11.1M | Buy |
47,970
+3,030
| +7% | +$617K | 0.47% | 48 |
|
|
2025
Q2 | $8.34M | Buy |
44,940
+260
| +0.6% | +$48.3K | 0.37% | 56 |
|
|
2025
Q1 | $9.36M | Buy |
44,680
+1,420
| +3% | +$276K | 0.46% | 48 |
|
|
2024
Q4 | $7.69M | Sell |
43,260
-11,100
| -20% | -$2.04M | 0.35% | 58 |
|
|
2024
Q3 | $10.7M | Sell |
54,360
-5,000
| -8% | -$933K | 0.46% | 50 |
|
|
2024
Q2 | $10.2M | Buy |
59,360
+5,900
| +11% | +$977K | 0.45% | 48 |
|
|
2024
Q1 | $9.74M | Buy |
53,460
+8,840
| +20% | +$1.52M | 0.45% | 49 |
|
|
2023
Q4 | $6.91M | Hold |
44,620
| – | – | 0.38% | 54 |
|
|
2023
Q3 | $6.65M | Sell |
44,620
-980
| -2% | -$144K | 0.41% | 50 |
|
|
2023
Q2 | $6.14M | Sell |
45,600
-21,320
| -32% | -$3.13M | 0.42% | 56 |
|
|
2023
Q1 | $10.7M | Sell |
66,920
-9,380
| -12% | -$1.43M | 0.68% | 46 |
|
|
2022
Q4 | $12.3M | Sell |
76,300
-8,540
| -10% | -$1.31M | 0.81% | 42 |
|
|
2022
Q3 | $11.4M | Sell |
84,840
-14,250
| -14% | -$2.04M | 0.8% | 44 |
|
|
2022
Q2 | $15.2M | Buy |
99,090
+6,610
| +7% | +$1.01M | 0.98% | 32 |
|
|
2022
Q1 | $15M | Sell |
92,480
-9,570
| -9% | -$1.39M | 0.8% | 38 |
|
|
2021
Q4 | $13.8M | Buy |
102,050
+7,110
| +7% | +$840K | 0.65% | 45 |
|
|
2021
Q3 | $10.2M | Sell |
94,940
-26,230
| -22% | -$3M | 0.53% | 52 |
|
|
2021
Q2 | $13.6M | Hold |
121,170
| – | – | 0.68% | 42 |
|
|
2021
Q1 | $13.1M | Buy |
121,170
+36,900
| +44% | +$3.95M | 0.72% | 40 |
|
|
2020
Q4 | $9.03M | Buy |
+84,270
| New | +$8.1M | 0.54% | 55 |
|
|
2020
Q1 | – | Sell |
-67,660
| Closed | -$5.99M | – | 130 |
|
|
2019
Q4 | $5.99M | Hold |
67,660
| – | – | 0.41% | 71 |
|
|
2019
Q3 | $5.12M | Buy |
+67,660
| New | +$4.64M | 0.38% | 76 |
|
|
2019
Q2 | – | Sell |
-62,800
| Closed | -$5.06M | – | 137 |
|
|
2019
Q1 | $5.06M | Sell |
62,800
-4,800
| -7% | -$393K | 0.41% | 78 |
|
|
2018
Q4 | $6.23M | Hold |
67,600
| – | – | 0.54% | 58 |
|
|
2018
Q3 | $6.39M | Buy |
67,600
+2,850
| +4% | +$270K | 0.49% | 60 |
|
|
2018
Q2 | $6M | Buy |
+64,750
| New | +$6.32M | 0.48% | 64 |
|
|
2017
Q3 | – | Sell |
-77,390
| Closed | -$5.61M | – | 136 |
|
|
2017
Q2 | $5.61M | Sell |
77,390
-26,270
| -25% | -$1.77M | 0.48% | 70 |
|
|
2017
Q1 | $6.75M | Hold |
103,660
| – | – | 0.6% | 57 |
|
|
2016
Q4 | $6.49M | Hold |
103,660
| – | – | 0.6% | 63 |
|
|
2016
Q3 | $6.54M | Hold |
103,660
| – | – | 0.62% | 56 |
|
|
2016
Q2 | $6.42M | Sell |
103,660
-6,160
| -6% | -$375K | 0.61% | 62 |
|
|
2016
Q1 | $6.27M | Sell |
109,820
-6,770
| -6% | -$377K | 0.6% | 61 |
|
|
2015
Q4 | $6.91M | Hold |
116,590
| – | – | 0.65% | 56 |
|
|
2015
Q3 | $6.34M | Buy |
+116,590
| New | +$7.59M | 0.64% | 62 |
|
Other funds holding ABBV
Nippon Life Global Investors Americas's ABBV Position: Q2 2026 in Review
Nippon Life Global Investors Americas reduced its AbbVie (ABBV) stake by 20% in Q2 2026, selling an estimated $2.21M and leaving 42,080 shares worth $10.6M. The position accounts for 0.42% of the portfolio, ranked #52.
Nippon Life Global Investors Americas first reported a position in ABBV in Q3 2015 and has held it in 37 quarters since. The position peaked at $15.2M in Q2 2022. 3,018 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Nippon Life Global Investors Americas held 42,080 shares of AbbVie worth $10.6M as of Q2 2026.
- Nippon Life Global Investors Americas sold 10,270 AbbVie shares in Q2 2026, an estimated $2.21M.
- AbbVie made up 0.42% of Nippon Life Global Investors Americas's portfolio in Q2 2026, its #52 holding.
- Nippon Life Global Investors Americas first reported a position in AbbVie in Q3 2015 and has held it in 37 quarters since.
- Nippon Life Global Investors Americas's AbbVie position peaked at $15.2M in Q2 2022.
- 3,018 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Nippon Life Global Investors Americas's 13F filing for Q2 2026, filed 6 Aug 2026.